-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | pick up shells
On July 23, Bristol-Myers Squibb (BMS) announced that it had voluntarily withdrawn Opdivo (nivolumab) as a single drug in the US market for hepatocellular carcinoma (HCC) that had previously been treated with sorafenib after consultation with the US FDA.
Opdivo received accelerated approval from the FDA for the first time in 2017 for this indication, and is the first immunotherapy drug approved for use in this population
BMS said that in the case of single drug withdrawal, Opdivo and Yervoy combination therapy is still approved for HCC patients who have progressed after sorafenib treatment or are intolerant to sorafenib
Liver cancer is the fourth leading cause of cancer deaths in the world, and hepatocellular carcinoma (HCC) is the most common type of liver cancer, and it is also the fastest rising cause of cancer-related deaths in the United States